Global PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Others PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others) – Industry Trends and Forecast to 2031.
PCR-based Infectious Diseases Market Analysis and Size
The global PCR-based infectious diseases market is driven by the rising incidence of infectious diseases worldwide, including respiratory infections, sexually transmitted infections, gastrointestinal infections, and vector-borne diseases, which is an important driver for market growth. Moreover, a rise in demand for rapid and accurate diagnostic methods is further propelling the market growth. However, a lack of reliable electricity, trained personnel, and laboratory facilities can hinder the widespread adoption of PCR-based tests, which is restraining the market growth.
Data Bridge Market Research analyzes that the global PCR-based infectious diseases market is expected to reach USD 7,720,895.13 thousand by 2031 from USD 4,737,570.00 thousand in 2023, growing with a CAGR of 6.6% in the forecast period of 2024 to 2031.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Thousand, Volume in Units, Average Selling Price in USD
|
|
Segments Covered
|
Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Others PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Hungary, Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
DNA Labs India, DrSafeHands, Ganesh Diagnostic & Imaging Centre Pvt. Ltd., Max Lab, MicroGen Diagnostics, pathlab, The Washington Travel Clinic, Clarewell Clinics, AZOVA, One Life Home Health Care Center, and LalPathLabs among others
|
Market Definition
The global PCR-based infectious disease market encompasses a dynamic ecosystem of products and services aimed at detecting and managing infectious pathogens through the application of polymerase chain reaction (PCR) technology. This market includes a diverse array of PCR assays, instruments, reagents, and software solutions tailored for the identification and characterization of various infectious agents, including viruses, bacteria, fungi, and parasites. PCR assays and kits are developed for specific pathogens, addressing a wide range of infectious diseases such as respiratory infections, sexually transmitted diseases, gastrointestinal illnesses, and emerging infectious threats. PCR instruments, including thermocyclers and real-time PCR systems, facilitate the amplification and detection of nucleic acid targets in clinical samples, while reagents and consumables support the laboratory workflow with essential components for PCR reactions. Moreover, software and bioinformatics tools aid in data analysis, interpretation, and reporting of PCR assay results, enhancing diagnostic accuracy and efficiency.
Global PCR-based Infectious Diseases Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing PCR-Based Research Activities
PCR has emerged as a key method in the field of infectious disease diagnosis and research because of its unmatched sensitivity, specificity, and efficiency in detecting and amplifying nucleic acids. The continuous progress in PCR technologies, in conjunction with a deeper comprehension of pathogen genetic composition, has enabled the creation of highly precise and expedient diagnostic assays. Continuous improvements in PCR technology, such as digital and real-time PCR, have increased the effectiveness and speed of diagnosing infectious diseases. These developments make it possible to identify pathogens more quickly and accurately, which allows for prompt intervention and treatment. The rise of point-of-care testing, which increases access to diagnostics in a variety of healthcare settings, is also facilitated by the ongoing improvement of PCR techniques.
- Rising Cases of Infectious Diseases
The rise of globalization, urbanization, and environmental degradation are some of the causes driving the rising frequency of infections globally, which has made robust diagnostic, therapeutic, and preventive treatments critically necessary. Public health is still seriously threatened by infectious diseases, which are made more difficult by newly developing pathogens and the reappearance of diseases that were previously under control.
Opportunities
- Disease Surveillance for Early Detection and Monitoring of Infectious Diseases
The capability of PCR-based tests to offer a robust tool for continuous disease surveillance presents a significant opportunity for market growth. These tests, characterized by high sensitivity and specificity, enable early detection and continuous monitoring of infectious diseases within populations. The real-time nature of PCR allows for the timely identification of pathogens, facilitating rapid response measures and effective containment strategies.
This proactive approach is crucial in preventing the spread of infectious diseases and mitigating their impact on public health. As a result, the opportunity lies in the market's ability to contribute to global health by providing advanced tools for disease surveillance, enabling early interventions and ultimately improving healthcare outcomes.
- Rising Innovations in PCR Technology
The ongoing innovations in PCR technology, notably the advancements in real-time PCR and multiplex PCR assays, present a substantial opportunity for market growth. These technological breakthroughs significantly enhance testing capabilities, offering more efficient, cost-effective, and comprehensive diagnostic solutions. Real-time PCR allows for the simultaneous amplification and quantification of nucleic acids, providing rapid and accurate results. Meanwhile, multiplex PCR assays enable the detection of multiple targets in a single reaction, contributing to a more thorough analysis of infectious agents. These advancements not only improve the speed and accuracy of diagnoses but also enhance cost-effectiveness by consolidating multiple tests into a single process.
Restraints/Challenges
- High Cost of PCR Test Services
PCR is a strong and accurate diagnostic technique that offers exact pathogen identification. However, the high cost of PCR testing is partly due to the advanced technology and the requirement for certain tools, materials, and qualified staff. Accessibility may be restricted by the cost of PCR-based diagnostics' implementation and maintenance, particularly in areas with limited resources and limited healthcare budgets. The diagnosis and containment of infectious diseases may be delayed due to the high cost of PCR tests, which can hinder large-scale testing operations.
There are other reasons that add to the high cost of PCR testing. First off, using the technology itself requires expensive specialized reagents and sophisticated equipment. The initial investment required by laboratories for establishing PCR capabilities is increased by the necessity for precision instruments such as thermal cyclers and nucleic acid extraction machines.
- Data Security and Privacy Concerns
The rising reliance on digital platforms for reporting and analyzing PCR test results brings forth a challenge to the market growth—data security and privacy concerns. Ensuring the confidentiality and secure handling of sensitive health data becomes paramount as the integration of digital technologies becomes more pervasive in the testing process. The potential vulnerabilities in data security raise apprehensions about unauthorized access, breaches, and the misuse of personal health information. Addressing these concerns is crucial not only for compliance with stringent data protection regulations but also for sustaining public trust in the testing process. A breach in data security could undermine confidence in the accuracy and reliability of PCR-based infectious disease testing, impacting both individuals and broader public health initiatives. Therefore, as the market continues to evolve and embrace digitalization, it must prioritize robust data protection measures and transparent privacy protocols to mitigate these challenges and maintain the trust of the public it serves.
Recent Developments
- In September 2023, the Human Papilloma Virus (HPV) Primary Screening Program was launched by pathlab. The HPV test can be conducted using the existing Liquid-Based Cytology (LBC) sample (SurePath) or by using a self-collected or clinician-collected vaginal swab. This program enhanced the diagnostic capabilities by offering flexibility in conducting HPV tests
- In August 2022, MicroGen Diagnostics expanded its operations in the field of targeted sequencing-based detection of orthopedic and urological infections, following the acquisition of new contracts and the initiation of outcomes studies. This strategic move not only broadened the company's service offerings but also opened up avenues for increased revenue through new contracts
- In June 2021, MicroGen Diagnostics expanded its proficiency and capabilities in non-clinical primary research through the acquisition of its partner lab, RTL Genomics. This strategic move empowered the company to broaden its scope of research activities, explore new avenues of scientific inquiry, and potentially lead to groundbreaking discoveries
Global PCR-Based Infectious Diseases Market Scope
The global PCR-based infectious diseases market is segmented into seven notable segments based on test type, infection, pathogen, PCR technology, patient type, testing, and end user. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Test Type
- Tuberculosis PCR Test
- Hepatitis PCR Test
- Human Immunodeficiency Virus (HIV) PCR Test
- Influenza PCR Test
- Human Papilloma Virus (HPV) PCR Test
- Gonorrhea PCT Test
- Salmonellosis PCR Test
- Rotavirus PCR Test
- Bordetella PCR Test
- H. Pylori PCR Test
- Norovirus PCR Test
- SARS (COVID-19) PCR Test
- Enterococcus PCR Test
- Chlamydia Trachomatis Genital PCR Test
- C.difficile (Clostridium Difficile) PCR Test
- Carbapenem-resistant Enterobacteriaceae (CRE) PCR Test
- Mycoplasma Genitalium (MG) PCR Test
- Methicillin-resistant Staphylococcus Aureus (MRSA) PCR Test
- Other PCR test
On the basis of test type, the market is segmented into tuberculosis PCR test, hepatitis PCR test, Human Immunodeficiency Virus (HIV) PCR test, influenza PCR test, Human Papilloma virus (HPV) PCR test, gonorrhea PCT test, salmonellosis PCR test, rotavirus PCR test, bordetella PCR test, H. Pylori PCR test, norovirus PCR test, SARS (COVID-19) PCR test, enterococcus PCR test, chlamydia trachomatis genital PCR test, C.Difficile (Clostridium Difficile) PCR Test, Carbapenem-resistant enterobacteriaceae (Cre) PCR Test, Mycoplasma Genitalium (Mg) PCR test, Methicillin-resistant staphylococcus aureus (Mrsa) PCR Test, and other PCR test.
Infection
- Viral Infection
- Respiratory Tract Infection
- Sexually Transmitted Infection
- Hospital Acquired Infections
- Other Infections
On the basis of infection, the market is segmented into viral infection, respiratory tract infection, sexually transmitted infection, hospital acquired infections, and other infections.
Pathogen
- Viral
- Bacterial
- Fungal
- Protozoa
- Others
On the basis of pathogen, the market is segmented into viral, bacterial, fungal, protozoa, and others.
PCR Technology
- RT PCR
- Multiplex PCR
- Others
On the basis of PCR technology, the market is segmented into RT PCR, multiplex PCR, and others.
Patient Type
- Geriatric
- Pediatric
- Adults
On the basis of patient type, the market is segmented into geriatric, pediatric, and adults.
Testing
- Laboratory Based Testing
- Point of Care Testing
On the basis of testing, the market is segmented into laboratory based testing and point of care testing.
End User
- Diagnostic Centers
- Hospital
- Academic and Research Institutes
- Community Health Centers
- Clinics
- Home Healthcare
- Others
On the basis of end user, the market is segmented into diagnostic centers, hospital, academic and research institutes, community health centers, clinics, home healthcare, and others.
Global PCR-based Infectious Diseases Market Regional Analysis/Insights
The global PCR-based infectious diseases market is segmented into seven notable segments based on test type, infection, pathogen, PCR technology, patient type, testing, and end user.
The countries covered in this market report are U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Hungary, rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa.
North America region is expected to dominate the market due to the presence of advanced healthcare infrastructure, technological innovation, particularly in the field of biotechnology and molecular diagnostics, and high demand for diagnostics. The U.S. is expected to dominate in the North America region due to the presence of advanced healthcare infrastructure, technological innovation, particularly in the field of biotechnology and molecular diagnostics, and high demand for diagnostics. Germany is expected to dominate in the Europe region due to their strong presence in international markets, with extensive distribution networks and sales channels and significant emphasis on research and development in the life sciences sector. China is expected to dominate in Asia-Pacific region due to its large population, high disease burden, rapid economic growth, and healthcare expansion.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and global brands, the impact of global tariffs, and trade routes are considered while providing forecast analysis of the country data.
Global PCR-based Infectious Diseases Market Competitive Landscape and Market Share Analysis
The global PCR-based infectious diseases market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the market.
Some of the major market players operating in the global PCR-based infectious diseases market are DNA Labs India, DrSafeHands, Ganesh Diagnostic & Imaging Centre Pvt. Ltd., Max Lab, MicroGen Diagnostics, pathlab, The Washington Travel Clinic, Clarewell Clinics, AZOVA, One Life Home Health Care Center, LalPathLabs and among others.
SKU-